On Thursday, India-based Global pharmaceutical company Lupin Limited announced the launch of Sildenafil for oral suspension, 10 mg/mL, after receiving approval from the United States Food and Drug Administration (FDA).
Sildenafil for Oral Suspension is a generic equivalent to Pfizer Inc’s Viagra Revatio for oral suspension. According to an estimation, Sildenafil for oral suspension (RLD Revatio) had annual sales of USD 64 million in the U.S in July 2022.

Sildenafil would be sold under the brand name generic Viagra. Sildenafil is used to treat pulmonary arterial hypertension and erectile dysfunction. The medication can be taken by mouth or injected into the vein by injection. However, there’s still no evidence of effectiveness in treating sexual dysfunction in women.

Pfizer originally discovered the medication in 1988 while looking for a treatment for heart-related chest pain. In the same year, the drug got authorization for medical use in the European Union and the United States.

Lupin is one of the leading manufacturers of generic drugs and sells both branded and generic formulations, biotechnology products, and pharmaceutical ingredients worldwide. The company is the biggest manufacturer of anti-TB medicines and is more focused on pediatric, CNS, diabetology, cardiovascular asthma, GI, anti-infective, and NSAID segments of the pharmaceutical market.